Shots:
- Organon has acquired the US regulatory & commercial rights for Tofidence, a biosimilar version of Actemra (tocilizumab), from Biogen, which retains manufacturing rights in the US
- As per the deal, Biogen will receive upfront, while Organon will assume Biogen’s obligation to pay Bio-Thera tiered annual net sales royalties & milestones
- Tofidence is a humanized anti-IL-6 mAb that will be available in 3 vial sizes—80mg/4mL, 200mg/10mL, & 400mg/20mL, for further dilution before IV infusion in the US
Ref: Businesswire | Image: Organon & Biogen
Related News:- Shanghai Henlius Biotech and Organon Reports EMA’s Validation of HLX11 (Biosimilar, Perjeta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
